Newer-generation antidepressants and suicide risk in randomized controlled trials: A re-analysis of the FDA database

The aim of this paper was to examine whether the use of newer-generation antidepressants, relative to placebo, bear an increased risk of (attempted) suicide when the analysis is based on the number of patients instead of patient exposure years (PEY.)